posit data updat continu
updat forecast estim oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
lead drug jakafi initi gain traction
drug approv sever myelofibrosi rare blood disord
jakafi monopoli mf market like continu especi
two lead competitor drug left play field
lacklust pivot trial data expand jakafi label
polycythemia vera late steroid refractori acut graft
versu host diseas may evalu drug essenti
thrombocythemia push peak sale
market jak inhibitor olumi baricitinib
approv europ rheumatoid arthriti earli
 partner
oral jak inhibitor xeljanz first market safeti concern
regard seriou infect rate malign weigh
market penetr olumi look slightli better
particular safeti issu though addit black box label
thrombocytosi expect cloud launch
also robust late-stag pipelin focus primarili
oncolog autoimmun indic provid
attract long-term growth opportun firm see
strong potenti topic version activ ingredi
jakafi ruxolitinib phase trial dermatolog
indic includ atop dermat vitiligo also think
potenti expand jak market global
itacitinib second-gener version jakafi
phase data first-lin treatment graft versu host diseas
later year
face major trial failur believ rest compani
robust pipelin support long-term growth trajectori
use cash gener success jakafi franchis
build suit asset evalu combin
immuno-oncolog indic program preclin
phase develop
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
focus discoveri develop small-molecul drug
firm lead drug jakafi treat two type rare blood cancer graft
versu host diseas partner novarti market
drug includ rheumatoid arthriti treatment olumi eli lilli
licens oncolog drug iclusig chronic myeloid leukemia
pipelin includ broad array oncolog autoimmun program
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
posit data updat continu oct
maintain per share fair valu estim
follow strong third quarter
slightli rais estim jakafi given stronger-than-
expect growth materi impact
valuat narrow moat support solid
continu jakafi potenti drug gain approv new
indic expand sale older indic
sale jakafi reach million
quarter rais full-year sale forecast
billion line new guidanc billion-
billion sale continu grow nice
establish myelofibrosi indic rapidli
polycythemia vera jakafi strong start graft-
versus-host diseas expect addit data
chronic gvhd set could expand jakafi
howev think upcom data two jak
program key futur growth ruxolitinib cream
vitiligo atop dermat well inhibitor
itacitinib first-lin treatment gvhd data
itacitinib expect year-end acut gvhd set
chronic data phase data ruxolitinib
come first half atop dermat
vitiligo recent data phase
vitiligo trial show continu improv respons
beyond week continu assum
probabl sale approach billion year
model beyond jak inhibit also file fda
approv pemigatinib second-lin cholangiocarcinoma
patient fgfr alter studi first-lin
set well bladder cancer tumor agnost
trial remain progress data roll
begin late also grow early-stag
pipelin immuno-oncolog expect see initi
data parsaclisib
slightli rais fair valu estim
per share follow jakafi approv
steroid-refractori acut graft versu host diseas also
due time valu money
olumi market eli lilli receiv
royalti percentag sale addit
develop regulatori mileston project
olumi royalti revenu near million
toward end forecast period roughli sale
also optimist compani partnership
checkpoint modul program direct gitr
howev yet attribut
valu model enter early-stag
jakafi continu strong perform mf pv
lacklust pivot result gilead momelotinib
cti pharma/baxalta pacritinib believ jakafi
near-term growth prospect improv drug
signific first-mov advantag
product could come market includ celgen
reviv fedratinib program think approv jakafi
polycythemia vera acut gvhd potenti label
expans essenti thrombocythemia could lead peak
 sale billion next-gener itacitinib
could mitig potenti pipelin gener
competit futur
valuat exclud incyt ido inhibitor program light
epacadostat phase trial failur metastat
melanoma combin merck inhibitor
keytruda anticip lacklust result remain
trial evalu epacadostat combin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
includ mf pv merit narrow econom moat rate
firm heavili depend jakafi sale nearli
revenu recent hit profit within
past year howev lack near-term threat
jakafi domin mf pv popul
incyt strong price power give us confid
compani gener return cost capit
forese futur
strong competit posit thank
jakafi franchis myeloprolif neoplasm
treatment approv food drug
administr myelofibrosi approv
polycythemia vera refractori patient drug
signific price power first-mov advantag
compet pipelin treatment jakafi solid efficaci
safeti profil patient popul high unmet
need allow compani set averag annual price
world-wide jakafi key patent expir
exclud potenti extens give incyt
signific runway build franchis expand
et gvhd indic
pipelin competit thin recent year
forese signific near-term threat
gilead drug momelotinib cti biopharma/baxalta
drug pacritinib previous led competit
acquisit impact biomedicin earli
celgen reviv anoth competitor program fedratinib
continu believ jakafi set high bar next round
novel molecul
myelofibrosi
 exit partnership
bristol/promedior antifibrot modul
expect use patient toler jakafi
low level platelet fail jakafi
therapi near-term prospect promis
view mani early-stag competitor trial way
partnership
astrazeneca bristol would provid upsid fair valu
given depend hand market
drug regulatori commerci risk pipelin
believ firm warrant high uncertainti rate
bull-cas scenario assum jakafi success
expand indic greater optim
pipelin candid greater oper leverag
result per share fair valu estim
bear-cas scenario model jakafi struggl
penetr mpn market failur earli stage
asset oper cost result signific
financi burden base case result fair
valu drop per share
myeloprolif neoplasm mpn market
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
arm phase data upadacitinib gilead
filgotinib look efficaci olumi ra
base top-lin result jak inhibitor
xeljanz first market despit steep competit
believ ra market could support multipl oral jak
inhibitor given high patient churn therapi
potenti near-term catalyst
progress dim time believ uptak
includ checkpoint inhibitor keytruda opdivo
howev believ earli candid
signific threat incyt jakafi franchis
robust pipelin mitig threat
futur jakafi sale compani sever early-
late-stag candid focus primarili oncolog
inhibitor provid
think posit moat trend base
potenti jakafi label expans progress
compani robust early-stag pipelin jakafi carv
strong defens market posit
addit label expans pv drug achiev
blockbust statu label expans acut chronic
graft-versus-host-diseas et could boost futur
compani procur
candid immuno-oncolog target posit
well increasingli key therapeut area
compani also sever earlier-stag candid focus
primarili oncolog autoimmun indic
recent partner checkpoint modul
program direct gitr
opportun remain rel unproven incyt
healthi pipelin give firm margin error believ
strategi develop combin oncolog
regimen bode favor competit advantag
rheumatoid arthriti drug olumi receiv multipl
setback last fda approv mg
dose mg black box warn due concern
imbal thrombot event treatment
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
jakafi first fda-approv
treatment rare blood disord known
myelofibrosi give strong price power
ojakafi label expans next-gener itacitinib
progress provid near-term catalyst firm
broad array pipelin oncolog
autoimmun program give firm larger margin
error
market upend monopoli
crowd market
thrombocytosi black box warn market
disadvantag
ido inhibitor trial failur melanoma
remov key near-term asset pipelin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
end billion cash
market secur limit debt balanc sheet
howev like biotechnolog compani
histor oper loss high cost
clinic trial research loss financ
larg offer equiti debt secur
collabor research develop fund arrang
develop mileston partner despit
heavi spend expect firm reach
sustain profit jakafi sale intern
royalti off-set high invest
histor post loss due heavi
research develop spend firm current
sound financi shape prolong loss eros
jakafi sale could put financi posit jeopardi
signific risk mani drug candid
never reach market jakafi phase trial failur
pancreat cancer significantli reduc
optimist predict exampl addit new
competitor jakafi could reach market erod
competit posit drug also small
molecul ensur gener competit
difficult stave goe patent melanoma
trial failur highli anticip ido inhibitor
epacadostat combin merck inhibitor
keytruda also highlight development risk associ
biotech compani furthermor baricitinib
demonstr attract profil conveni oral
formul ra market highli competit
demonstr launch pfizer xeljanz
disappoint even though first oral
product market upadacitinib secur
clean prescrib label fda approv expect third
quarter drug could give olumi run
money market olumi approv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
less efficaci mg dose amid concern
thrombot event mg dose
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
hoppenot took ceo join
presid oncolog novarti believ
hoppenot experi establish pharma firm
valuabl pipelin matur firm
transit one-drug start-up matur
diversifi biopharmaceut compani given firm
lack sustain profit past focus
deploy capit research develop
result capital-alloc decis
judg manag howev believ firm
licens agreement eli lilli olumi dictat
favor term compani sharehold alik
respons research
develop cost entitl substanti royalti
mileston payment although execut
 commerci jakafi well without previou
experi view think would
difficult go alon competit rheumatoid arthriti
market also like manag strategi deploy
cash gener jakafi franchis acquir early-stag
ceo/chairman board/
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
nich indic could bode well use patient
alter first-lin cholangiocarcinoma
phase bladder cancer phase data
tumor tumor agnost trial start beyond
pemigatinib grow early-stag pipelin
immuno-oncolog expect see initi data
parsaclisib
second-quart result line
expect slightli increas fair valu
estim per share per share account
recent approv jakafi third key indic
 may steroid-refractori acut graft versu host
diseas report growth jakafi driven
mostli volum keep full-year estim
revenu billion still within
manag narrow guidanc
strong pipelin oncolog immunolog support
posit moat trend follow heel jakafi
recent label expans expect jakafi data
larger studi chronic acut gvhd come later
year next-gener inhibitor itacitinib also
phase studi gvhd first-lin treatment
produc data patient acut diseas
posit phase result ruxolitinib cream vitiligo
dermatolog autoimmun condit effect
treatment world congress dermatolog meet
june think ruxolitinib cream could becom solid
treatment option given respons rate
improv measur facial sever
highest dose versu placebo vitiligo
phase trial commenc later year phase data
atop dermat expect encourag
potenti program assum
probabl sale approach billion year
also plan file approv pemigatinib later
year cholangiocarcinoma fgfr alter
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
equival
net properti plant equip
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
